← Tierney Baum

What podcasts say about Tierney Baum

Every statement, with the speaker, the exact quote and the moment it was said.

What Tierney Baum has said on podcasts

9 statements · 4 positive · 3 negative · 2 neutral

  1. on Merck and Moderna personalized neoantigen vaccinePositiveNov 17, 2026· BioCentury This Week

    Merck and Moderna’s personalized neoantigen vaccine modality met a late-stage trial objective.

    “this modality could meet in a late stage trial.”

    Listen at 9:45

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  2. on personalized neoantigen vaccinesNeutralNov 17, 2026· BioCentury This Week

    The neoantigen vaccine field likely needs several years for solid answers.

    “we're probably still a ways out a couple years out from beginning to really get more solid answers to some of these questions”

    Listen at 11:58

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  3. on ModernaPositiveNov 17, 2026· BioCentury This Week

    Moderna and Merck’s neoantigen program leads the pipeline with the most Phase 3 trials.

    “they're still clearly ahead in the pipeline. They have the most phase three trials.”

    Listen at 12:23

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  4. on ModernaNeutralNov 17, 2026· BioCentury This Week

    The Moderna and Merck program’s primary readout is not expected until 2028.

    “this one's still not going to reach its primary readout till 2028.”

    Listen at 12:30

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  5. on BioNTechNegativeNov 17, 2026· BioCentury This Week

    BioNTech and Roche’s neoantigen program has struggled to demonstrate clinical efficacy.

    “that has really struggled to show efficacy in the clinic, including as monotherapy plus Keytruda.”

    Listen at 12:54

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  6. on BioNTechNegativeNov 17, 2026· BioCentury This Week

    BioNTech and Roche’s Phase 3 trial failed its progression-free-survival endpoint.

    “that failed to meet its progression-free survival endpoint.”

    Listen at 13:15

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  7. on Avaxion EVX01PositiveNov 17, 2026· BioCentury This Week

    Avaxion’s EVX01 study showed deepened responses, a 75% response rate, and four complete responses.

    “the two-year results did show a deepening of response. above Keytruda with 75% objective response rate and four complete responses.”

    Listen at 14:25

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  8. on personalized neoantigen vaccine manufacturingPositiveNov 17, 2026· BioCentury This Week

    mRNA and DNA vaccines manufacture faster than peptide vaccines because peptides require separate synthesis.

    “mRNA and DNA have faster manufacturing times because everything can be encoded on one strand of genetic material, whereas for peptides, it takes longer because... Everyone has to be synthesized separately.”

    Listen at 16:30

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  9. on personalized neoantigen vaccine manufacturingNegativeNov 17, 2026· BioCentury This Week

    Decentralized manufacturing is currently the biggest bottleneck for smaller vaccine developers.

    “the biggest bottleneck right now is having decentralized manufacturing for smaller players.”

    Listen at 16:51

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.